Chugai Seiyaku Kabushiki Kaisha

F. Hoffmann-la Roche Ag

Bernhard Reis

Toshihiko Ohtomo

Sebastian Dziadek

Ruey-Min Lee

Gwen Nichols

Thomas Schindler

Anton Belousov

Takayoshi Tanaka

Ruediger Rueger

Gong Chen

Ya-Chi Chen

Yasuo Sugitani

Hua Zhong

Oscar Puig

Steven D Blotner

Lori Jukofsky

Ana Patricia Bento Pereira Da Silva

Barbara Ecabert

Everson Nogoceke

Moritz Marcinowski

Michel Achille Edouard Theron

A method is provided for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or for determining the continuation of GPC3-targeting drug therapy for a patient treated with GPC3-targeting therapy. The method includes determining the number of an immunocyte or an expression level of a molecule expressed on the immunocyte in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the number of the immunocyte or the expression level of the molecule expressed on the immunocyte is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. GPC3-targeting drugs and drug preparations for use according to the disclosed methods are also provided.

GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy

Growing community of inventors

Basel, Switzerland

Bernhard Reis